VIA Pharmaceuticals (VIAP) Stock Price, News & Analysis

Company Overview

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 41,946 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIAP Stock Analysis - Frequently Asked Questions

How do I buy shares of VIA Pharmaceuticals?

Shares of VIAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VIAP
• CUSIP: N/A
• CIK: N/A
• Web: www.viapharmaceuticals.com
• Phone: (415) 283-2200
• Fax: 415-283-2201
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.32